e.g. mhealth
Search Results (1 to 10 of 15 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIR Formative Research
- 3 JMIR Research Protocols
- 3 Journal of Medical Internet Research
- 2 JMIR Human Factors
- 2 JMIR Public Health and Surveillance
- 1 JMIR Medical Education
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Medical Informatics
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Disruption in access for patients who use buprenorphine for OUD and patients who use chronic opioid analgesic therapy may have contributed to these issues.
Patients receiving opioids for chronic pain or buprenorphine for OUD may be more likely to experience disruptions in care since buprenorphine and chronic opioid analgesic therapy are controlled substances with restrictions on prescribing [22-26].
JMIR Form Res 2025;9:e66596
Download Citation: END BibTex RIS
The resulting themes related to buprenorphine product-specific TINs are accessing buprenorphine (Acc Bup), taking buprenorphine (Take Bup), experiencing psychophysical effects (Psyphy), co‑occurring substance use (Co SU), and tapering buprenorphine (Tape Bup). Some of these themes reflect the early stage of recovery (eg, Acc Bup and Take Bup), while others reflect the recovery continuum (eg, Co SU and Psyphy). The definitions of these themes are presented in the Results section.
J Med Internet Res 2025;27:e68886
Download Citation: END BibTex RIS
Buprenorphine, a medication used to treat opioid use disorder (OUD), reduces relapse and overdose risk and improves long-term treatment outcomes in individuals with opioid addiction. Studies have established the safety and efficacy of buprenorphine induction in both office-based and unobserved (ie, home) settings.
JMIR Form Res 2025;9:e72872
Download Citation: END BibTex RIS
Therefore, those symptoms, or their anticipation, can impede successful transmucosal buprenorphine discontinuation [19,26-28]. Patients report challenges with tapering buprenorphine, particularly with the transition from 2 mg transmucosal buprenorphine to no treatment, using strategies such as cutting strips or dissolving tablets in water to achieve smaller buprenorphine doses to facilitate tapering and minimize withdrawal symptoms [29].
J Med Internet Res 2025;27:e71245
Download Citation: END BibTex RIS
One Medicaid data study following over 90,000 patients showed remarkable positive outcomes from telemedicine initiation of buprenorphine treatment, including better odds of 90-day treatment retention than if initiation occurred in person [12]. In a scoping review from 2008 to March 18, 2021, reviewers found that telehealth technology in SUD treatment increased access and adherence to buprenorphine and generally showed higher patient satisfaction and comparability to in-person retention rates [11].
JMIR Hum Factors 2025;12:e65419
Download Citation: END BibTex RIS
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey
In part, this enabled crucial access to buprenorphine for opioid use disorder treatment [4,5]. Now, consumers and stakeholders are calling for new policy that enables continued access to mental health care and substance use treatment, including medication-based treatment, via telemedicine [6]. The challenge is to develop evidence-based policy that supports safety while enabling critical health care access.
JMIR Form Res 2025;9:e63251
Download Citation: END BibTex RIS
Furthermore, patients taking medication for OUD (MOUD), including either buprenorphine or methadone, are of specific interest because of their risk for unmanaged pain-triggering relapse. Indeed, patients taking MOUD often have difficulty accessing nonpharmacological treatments and many report unmanaged pain as the primary reason for opioid relapse [24].
JMIR Res Protoc 2024;13:e53784
Download Citation: END BibTex RIS
Buprenorphine and naloxone (BUP and NAL) can reduce opioid overdose deaths by at least 70%, decrease opioid misuse, and improve quality of life [3-6]. Because of its demonstrated efficacy, the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, the American Society of Addiction Medicine, and the American Academy of Addiction Psychiatry endorse the use of medications for opioid use disorder in the treatment of opioid use disorder (eg, BUP and NAL and methadone).
JMIR Form Res 2023;7:e40437
Download Citation: END BibTex RIS
In combating the opioid crisis, buprenorphine is the drug of choice when adhering to an evidence-based clinical standard of care. However, the Drug Addiction Treatment Act of 2000 mandates those clinicians receive a waiver known as the Drug Enforcement Administration (DEA)-X waiver in order to prescribe buprenorphine [1].
JMIR Hum Factors 2023;10:e40244
Download Citation: END BibTex RIS
The re SET-O PDT was authorized by the FDA in 2018 for patients with OUD being treated with buprenorphine.
JMIR Res Protoc 2023;12:e43122
Download Citation: END BibTex RIS